Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PCTP | Q9UKL6 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CDC42 | P60953 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453635 | 0.92 | TP53 (0.75) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13470274 | 0.92 | MAPT (0.69) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13469892 | 0.92 | MAPT (0.69) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13469953 | 0.91 | TP53 (0.68) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13470364 | 0.91 | ALDH1A1 (0.57) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13453687 | 0.90 | MAPT (0.79) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13453682 | 0.89 | MAPT (0.78) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13453688 | 0.89 | MAPT (0.78) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13470297 | 0.88 | ALDH1A1 (0.56) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13469737 | 0.88 | KMT2A (0.69) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | TP53 4776/4885MAPT 781/4885MEN1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.